SCHEMBL807699

SCHEMBL807699

Cc1ccncc1N1CCc2c([nH]c3ccccc23)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 3/20 0.47
RAB9A P51151 3/20 0.47
HPGD P15428 3/20 0.47
NPC1 O15118 2/20 0.47
TSHR P16473 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 11/20 0.46
CYP1A1 P04798 11/20 0.46
CYP1B1 Q16678 11/20 0.46
LMNA P02545 2/20 0.46
CYP3A4 P08684 2/20 0.46
POLB P06746 2/20 0.46
PDE5A O76074 1/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
THPO P40225 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797995 0.73 PDE5A (0.52) KDM4EALDH1A1HSD17B10RAB9APDE5A
SCHEMBL798870 0.73 CYP11B2 (0.47) ALDH1A1RAB9ANPC1CYP1A2PKM
SCHEMBL793787 0.72 CYP11B2 (0.35) HTR7
SCHEMBL3781062 0.71 SCN9A (0.39) HSD17B10LMNAHTR7HTR6HTT
SCHEMBL807963 0.71 GRM1 (0.40) CYP1A2HTR2AHTR2C
SCHEMBL794339 0.71 CYP17A1 (0.37) CYP1A2CYP3A4HTR1AMAPTHTR2A
SCHEMBL1311759 0.71 KDM4E (0.64) KDM4EALDH1A1HSD17B10RAB9AHPGD
SCHEMBL6238228 0.71 KDM4E (0.56) KDM4EALDH1A1HSD17B10RAB9AHPGD
SCHEMBL797921 0.70 ACHE (0.41) CYP3A4ACHE
SCHEMBL5740905 0.70 CYP1A1 (0.78) KDM4EALDH1A1HSD17B10RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 KDM4E 530/4885ALDH1A1 68/4885HSD17B10 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.